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Abstract
The remarkably good prognosis and long-term survival in dif-
ferentiated thyroid cancer (DTC) are significantly reduced in
patients with distant metastasis (DM). Multi-site metastases are
associated with a high mortality rate reaching 92% at 5 years
necessitating early diagnosis and treatment. The most com-
mon site of metastases are the lungs, followed by the bone,
with the former having better prognosis than the latter due to
late detection. A number of factors contribute to the develop-
ment of DM including large and multifocal primary tumour, ex-
trathyroidal extension, aggressive histology and advanced age.
In patients with good 131I uptake, 131I therapy appears highly
effective and should be offered up to a cumulative activity of 22
GBq. Other measures such as surgery, radiotherapy, arterial
embolisation and cementoplasty may be required.
If there is low or no 131I uptake, FDG-PET should be obtained
due to its prognostic impact. It may help in selecting patients
for other modalities such as cytotoxic chemotherapy and redif-
ferentiation therapy by 13-cis retinoic acid. The development of
tyrosine kinase inhibitors has raised hopes in providing alter-
native therapy for bone metastasis, especially in older age
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Although differentiated thyroid cancer (DTC) is usually of good
prognosis [1], patients with distant metastases (DM) (4–15%) [2–6]
are known to have a markedly reduced survival rate of 50% at
5 yrs, decreasing to 13–33% at 10 yrs [5, 7–12]. However, a re-
cent study by Durante et al. showed a distinction between pa-
tients with 131I uptake with persistent imaging abnormalities, who
had an overall survival at 10 yrs of 29%, and those who had
a negative 131I uptake where survival reached 92% [13]. The
10-year survival was as low as 10% in patients in whom metastas-
es showed no initial 131I uptake. The importance of early diagnosis
of functioning DM is thus clearly highlighted. However, the true
prognosis for an individual patient with stage IV thyroid cancer is
still difficult to assess due to differences in reported outcomes.
This is due the heterogeneous analysis of results with regard to
timing of development of metastasis, site and extent of disease,
age of the patients, histology of the tumour and treatment of the
metastatic disease.
Distant metastates are synchronous with the primary diagno-
sis in 5 to 45 % of patients [6, 11, 12] but could be encountered 5
or 10 years after the initial treatment, thus justifying the prolonged
follow-up of thyroid cancer patients [9, 10, 14, 15].
The most common site of metastasis is the lung followed by
the bones. Other metastatic areas are less common and involve
the mediastinum, brain, liver, skin and so forth. Multi-site disease
is associated with a higher rate of mortality that can reach 92% at
5 yrs [7, 12, 16, 17].
Patients with lung metastases have a better outcome com-
pared to other groups [11, 18] whereas bone metastases are usu-
ally associated with a poor prognosis [7, 12, 13, 18–26, 28, 29],
which might partly be due to the fact that they are rarely detected
at an early stage. Among 109 patients with bone metastases de-
scribed by Bernier et al., only four (4%) had both positive radioio-
dine uptake and negative standard X-ray examination [19]. Simi-
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larly, in the study by Durante et al. [13], radiographs were nega-
tive at presentation in only eight (7%) of 115 patients. In our recent
series of 16 bone metastases among 921 consecutive thyroid
cancer patients [30], we found eight patients (50%) in whom bone
metastases were first revealed by 131I scanning, and in whom com-
plementary radiological studies were negative. Six of these pa-
tients had a very good response to 131I therapy with 131I uptake
and thyroglobulin (Tg) levels becoming undetectable or showing
a sharp fall. One patient refused 131I therapy and bone metastas-
es became visible on MRI within one year and the Tg level rose
10-fold.
When it is thought that a patient is at high risk of multiple bone
metastases, it may be important to make this diagnosis by con-
ventional imaging before withdrawal of thyroid hormone to avoid
dramatic potential complications such as neurological compres-
sion at the site of spine metastases that may occur at the time of
131I therapy. These patients may require surgery or cementoplasty
before hormone withdrawal and 131I therapy. As patients with DM
are usually 10 to 15 years older than non-DM controls [9], the
presence of DM should be thus suspected in the case of increas-
ing age, as well as in patients with already known DM where mul-
tiple organ involvement is possible, but also increasing primary
tumour size, extrathyroidal extension, aggressive histology (poor-
ly differentiated follicular tumours, Hürthle cell tumours [31, 32]
and insular tumours [33]). Lastly, male gender [9, 33] and multifo-
cality of the primary tumour [34, 35] have also been described as
predisposing factors.
The treatment of DTC with metastasis requires total/near-
total thyroidectomy followed by radioiodine therapy, which is the
treatment of choice in iodine-avid metastases, and which re-
sponds favourably to 131I therapy. This is supported by the litera-
ture [3, 13, 26, 36, 37]. However, as already mentioned, bone
metastases may require additional therapy such as surgery, ra-
diotherapy and/or alternative treatments by arterial embolisation
[38] and cementoplasty in emergencies (vertebral compression,
fracture, brain metastasis) or as a first line therapy to reduce the
tumour burden or as preparation for 131I therapy. Lastly, treat-
ment with bisphosphonates may delay tumour progression and
palliate symptoms.
However, high cumulative activities of radioiodine (> 22 GBq;
600 mCi) are associated with a significantly increased risk of leu-
kaemia (which may differ according to whether 131I is used alone
or in combination with external beam radiation therapy) [39] and
secondary cancers [39, 40]. For this reason, 131I should be re-
peated only when benefits are expected. Another potential risk
from 131I is pulmonary fibrosis in patients with diffuse pulmonary
metastases who receive repeated activities of radioiodine over
short intervals of time; pulmonary function should therefore be
periodically assessed during 131I therapy, especially in young pa-
tients [41]. Therefore, the decision to continue or stop 131I therapy
at 22 GBq should depend on the risk associated with metastatic
disease and should be taken on an individual basis [14, 15].
131I treatment appears highly effective in younger patients with
131I uptake and with small metastases. In the study of Durante et al
[13], the best responses (92% 10-yr survival rate) were observed
in patients younger than 40 years old with papillary or follicular
well-differentiated subtypes and a limited extent of disease; such
patients should be treated until the disappearance of any uptake
or until a cumulative activity of 22 GBq is attained. However, in
patients who continue to have uptake, the beneficial effects of 131I
are difficult to quantify but probably contribute to the reduced 10-
yr survival rate that can reach 30% [3, 12, 13, 30, 36]. This is in-
deed significantly better than the 10-yr survival rate of 10% ob-
served in patients without any detectable uptake, and may be re-
lated to different tumour biology and to the beneficial effects of
radioiodine therapy [13].
In patients with stable disease over several years with a good
quality of life, we recommend that 131I therapy be withheld after 22
GBq and that such patients be monitored with spiral CT scans or
MRI and Tg assays, and that further 131I therapy only be given in
the event of disease progression [36].
Whenever possible, FDG-PET should be obtained both in
patients with non-functioning metastases or those with function-
ing macrometastases. We believe FDG-PET is an important com-
plementary imaging study in these patients because of its con-
firmed prognostic impact [42]. It might also help to select candi-
dates for new therapeutic trials in cases of high FDG uptake [43].
Patients with large metastases, poorly differentiated carcino-
mas and with low or no 131I uptake may be candidates for thera-
peutic trials with new agents, since the current therapeutic op-
tions for such patients are limited [43]. Cytotoxic chemotherapy
(especially doxorubicin) has proven to be ineffective in these pa-
tients. Redifferentiation therapy by 13-cis retinoic acid (RA) which
can induce 131I uptake in about 40% of such patients [44–48] gave
great hope in the end of the nineties in patients with loss of differ-
entiation [49], including the loss of radioiodine uptake, but unfor-
tunately the results were controversial [50, 51]. All-trans-retinoic
acid (ATRA) has recently been studied [52] and might deserve
further investigation. A recent study has demonstrated that his-
tone modification patterns may explain RA-refractoriness in DTC
patients and may suggest a potential benefit of combined tran-
scriptional and differentiation therapies [53].
The development of tyrosine kinase inhibitors has recently
changed therapeutic strategies in oncology [54], and their role in
thyroid cancer management has been underlined in two recent
reviews [43, 55]. This new strategy may represent a new hope for
such patients, particularly those of older age groups with poorly
differentiated tumours who have no or low radioiodine uptake, large
metastases, location in bones, rapidly progressive disease and
high uptake of FDG. It may also help patients with initial uptake
but poor or no response to radioiodine treatment and those with
no initial uptake of radioiodine, especially when the disease is pro-
gressive. The results of molecular targeted therapies and anti-
angiogenic agents, which are being studied in prospective con-
trolled trials, are therefore anticipated with great interest.
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